Strain C57BL/6 (B6) mice infected with LP-BM5 murine leukemia virus (MuLV) develop a disease which combines abnormal lymphoproliferation with profound immunosuppression and has many features in common with human acquired immunodeficiency syndrome induced by HTLV-III/LAV retroviruses. To determine whether this LP-BM5 MuLV infection would affect the innate resistance of B6 mice to a naturally occurring, highly virulent murine pathogen, mice were exposed to ectromelia virus at various times after treatment with LP-BM5 viruses. At week 4 after infection with LP-BM5, mice challenged with ectromelia virus were unable to generate a humoral immune response to this virus, and between weeks 8 and 10 after infection, challenged mice lost the ability to generate an ectromelia virus-specific cytotoxic-T-cell response. Loss of the cellular immune responses to ectromelia virus was associated with an increased susceptibility to the lethal effects of the virus.
Retroviruses are widely distributed among the vertebrate species and have been studied intensively for insights into neoplasia; however, not all retroviruses are oncogenic for the host. For example, in certain strains of mice, murine leukemia viruses (MuLV) cause a number of nonneoplastic disorders such as spongiform encephalomyelopathy (8, 10) , the early graying of coats (17) , and deformed whiskers (23) .
Recently a nonneoplastic, progressive, lymphoproliferative disease associated with polyclonal-B-cell activation, hypergammaglobulinemia, and profound immunosuppression (18, 21) has been observed in adult C57BL/6 (B6) mice infected with MuLV initially isolated by Lateret and Duplan (15) . A continuous cell line obtained from mice with this disease (9) produces a mixture of ecotropic and mink cell focus-inducing (MCF) viruses, termed LP-BM5 MuLV (18) . The disease-inducing component in this mixture appears to be MCF virus that is totally dependent on the nonpathogenic helper ecotropic MuLV for spread within the host (R. A. Yetter, unpublished observations).
Although the syndrome induced by LP-BM5 MuLV has many histologic and immunologic features in common with human acquired immunodeficiency syndrome (AIDS), B6 mice infected with LP-BM5 MuLV appear to die with respiratory failure secondary to mediastinal lymph node enlargement, whereas AIDS patients succumb to a variety of opportunistic infections. Since laboratory mice live in a highly regulated environment, it was reasoned that the differences between the terminal stages of LP-BM5 virusinduced disease and AIDS might reflect a lack of exposure of LP-BM5-infected mice to normal murine pathogens. To test this hypothesis, adult B6 mice were infected with LP-BM5 MuLV and then challenged with ectromelia virus, an agent that causes an inapparent infection and no mortality when administered to immunocompetent B6 mice by footpad inoculation (19, 25) . * Corresponding author.
MATERIALS AND METHODS
Mice. C57BL/6J mice of both sexes were used at 4 to 6 weeks of age. Mice were purchased from the Jackson Laboratory, Bar Harbor, Maine.
Cell culture. BS-C-1 cells (a continuous African green monkey kidney cell line) were used exclusively for production of ectromelia virus stocks and for determination of virus infectivity (6) .
MuLV LP-BM5. SC-1 cells were cocultivated with mitomycin C-treated lymph node cells from a B6 mouse infected with LP-BM5 MuLV containing a mixture of ecotropic and MCF MuLV. Twenty-four-hour culture supernatants of these cells contained 6.3 x 104 PFU of ecotropic virus per ml and 1.3 x 104 focus-forming units of MCF virus per ml. Throughout this communication, the designations LP-BM5 MuLV and LP-BM5 MuLV mixture refer to a combination of the ecotropic and MCF viruses.
Ecotropic virus was biologically cloned by two limiting dilutions in SC-1 cells. The cloned-virus preparation was shown to contain 5.0 x 103 PFU of ecotropic virus per ml (24) and to be free of MCF virus by both focus-forming and fluorescent antibody assays in mink lung cells (12) .
Ectromelia virus strain 79. Ectromelia virus strain 79 was isolated during an outbreak of mousepox at the National Institutes of Health in 1979 and 1980 (1) and biologically cloned as described previously (6) . Sucrose gradient-purified virus (11) , which was divided into portions and stored at -70°C until use, was used in all experiments. All manipulations involving live virus were carried out in a class II hood at biosafety level 3.
Ectromelia virus plaque assay. Ectromelia virus infectivity was estimated by inoculations of BS-C-1 confluent monolayers (60-mm diameter) with 0.5 ml of serial 10-fold dilutions of virus in phosphate-buffered saline (without Ca2+ or Mg2+) plus 0.1% bovine serum albumin (6 effector-to-target ratios (see below). After 4 h at 37°C, 0.1 ml of the culture supernatant was removed to measure the release of 51Cr. Spontaneous release of 51Cr was determined for target cells incubated with medium alone, and maximum 51Cr release was determined by lysis of targets with distilled water. Data are presented as percent specific release, defined as 100 x (experimental cpm -spontaneous cpm)/(total cpm -spontaneous cpm).
RESULTS
Ectromelia virus-induced mortality in B6 mice infected with LP-BM5 MuLV. Ectromelia virus is a naturally-occurring murine pathogen that is probably transmitted in the wild through skin abrasions (7) . In the laboratory, footpad inoculation closely approximates this route of infection. Strains of inbred mice vary considerably in their response to ectromelia virus challenge by this route (25) . Some strains, such as A/J, rapidly succumb to a systemic infection associated with severe hepatic and splenic necrosis and high levels of virus (>107 PFU/g) in both types of tissue. Other strains, such as B6, experience no mortality and little if any morbidity, and they replicate virus at significantly lower levels (<105 PFU/g) in spleen and liver, when infected with high doses of virus by a peripheral route of inoculation (19, 25) . Strain variations in response to this infection have been shown to be genetically determined (26) and in part may reflect differential capacities to generate virus-specific CTL responses (2, 3, 20) .
Earlier studies of adult B6 mice infected with LP-BM5 MuLV demonstrated that they rapidly lost their ability to respond specifically to a variety of antigenic stimuli in vitro (18) . To determine whether this MuLV strain would also affect the ability of mice to control an in vivo infection, B6 mice inoculated as adults with LP-BM5 virus mixture or with ecotropic virus alone were challenged with ectromelia virus and observed for morbidity and mortality (Fig. 1) e The 14-week data sets were from a second experiment in which no challenged mice inoculated with the LP-BM5 mixture survived challenge (see Fig. 1 ).
The ability of LP-BM5-infected mice to mount an ectromelia virus-specific CTL response was determined at two different times: week 8 after LP-BM5 infection, when most mice were resistant to the lethal effects of ectromelia virus, and week 10 after infection when most mice were susceptible (Fig. 1) . When assayed at day 7 after ectromelia virus challenge, mice infected 8 weeks earlier with the LP-BM5 virus mixture had CTL levels that were approximately half those of mice infected with ecotropic virus alone ( Fig. 2A, B) . By comparison, no ectromelia virus-specific CTL responses were obtained from the spleen cells of mice inoculated 10 weeks earlier with the LP-BM5 virus mixture and tested for CTL activity on day 5 (Fig. 2C, D) , 7 (Fig. 2E,  F ), or 10 ( Fig. 2G, H) after challenge with ectromelia virus.
In this experiment, 6 of 12 mice inoculated with the LP-BM5 virus mixture, in parallel with the mice used in the week 10 CTL assays, died after infection with ectromelia virus. All mice had high virus titers in the spleen and liver (Table 3) . Five additional mice sacrificed at day 9 after challenge exhibited extensive ectromelia virus-induced splenic and hepatic necrosis. The six surviving mice were sacrificed at day 24 after ectromelia virus challenge for histopathologic studies and assays for ectromelia virus in spleen and liver tissues. All six mice had histologic changes in the lymph nodes and spleen consistent with advanced LP-BM5-induced disease, but no infectious ectromelia virus was detected in spleen or liver tissue. The mice were known to have been infected, as they previously had shown primary lesions at the sites of inoculation.
DISCUSSION
The data presented here demonstrate that infection of adult B6 mice with the LP-BM5 virus mixture rendered this normally highly resistant strain susceptible to the lethal effects of ectromelia virus (Fig. 1) . Mortality was observed in some mice challenged with ectromelia virus as soon as week 6 after inoculation with the LP-BM5 virus mixture, and when challenged 14 MuLV mixture, as no mortality was observed in ectromelia virus-challenged mice previously infected with the LP-BM5 ecotropic virus alone ( Fig. 1 ; Tables 1 and 3; data not  shown) .
Earlier studies demonstrated that MCF viruses present in the LP-BM5 mixture rapidly induce profound suppression of a variety of T-and B-cell functions measured either in vitro or in vivo (18) . In this report, in vivo antibody responses to challenge with ectromelia virus were found to be depressed as early as week 4 after infection with the LP-BM5 virus mixture (compare the week 4 mixed infection with the week 10 or 14 LP-BM5 ecotropic infection [ Table 2 ]). Mice with no virus-specific antibody responses were still resistant to ectromelia virus-induced mortality, a result consistent with earlier studies indicating that antibody plays little if any role in recovery from mousepox (2, 3) .
By comparison, the loss of virus-specific CTL responses in primary in vitro assays of spleen cells from ectromelia virus-infected mice was correlated with the extent of ectromelia virus-induced mortality (Fig. 1, 2) . Virus-specific CTL activity was observed, at reduced levels, in mice challenged with ectromelia virus at week 8 after infection with the LP-BM5 virus mixture, a time at which most mice were still resistant to ectromelia virus-induced mortality. However, on challenge with ectromelia virus at week 10 after infection with the LP-BM5 virus mixture, ectromelia virus-specific CTL responses were no longer detectable, and ectromelia virus-induced mortality of 50% was observed (Table 3 , Fig. 2 ). The mechanism(s) responsible for the clearance of ectromelia virus in mice surviving challenge at 10 weeks after infection with the LP-BM5 virus mixture is not known but may reflect the influx of CTL from sites not assayed (e.g., the lymph node) or the activity of Mac-1+ cells present at increased frequency in the spleens of mice infected with the LP-BM5 virus mixture (18) . A role for mononuclear phagocytes in the clearance of ectromelia virus from infected tissues was demonstrated previously (4, 5, 22) , and ongoing studies of peritoneal macrophages from B6 mice exposed to LP-BM5 mixed-virus infection indicate that these cells function normally, at least through week 12 after infection (C. Nacy and R. Yetter, unpublished observations). Taken together with the results from our earlier studies (18) , these data extend the parallels between the effects of LP-BM5 infection on mice and the effects of HTLV-III/LAV infection on humans. Both diseases are associated with lymphadenopathy, polyclonal-B-cell activation, progressively severe immunosuppression, and enhanced susceptibility to the lethal effects of otherwise innocuous infections (13, 14, 16) . Further studies of this retrovirus-induced murine AIDS may thus provide important insights into the host-virus interactions responsible for the development of AIDS.
